Cargando…

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin

A 55-year-old Japanese man with a 3-year history of type 2 diabetes mellitus was admitted to our hospital for upper abdominal pain. Control of diabetes mellitus was good with voglibose and metformin, with sitagliptin added to this regimen 8 months prior. His pancreatic enzyme levels were elevated, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sue, Mariko, Yoshihara, Aya, Kuboki, Koji, Hiroi, Naoki, Yoshino, Gen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576864/
https://www.ncbi.nlm.nih.gov/pubmed/23467428
http://dx.doi.org/10.4137/CCRep.S10856
_version_ 1782259885129334784
author Sue, Mariko
Yoshihara, Aya
Kuboki, Koji
Hiroi, Naoki
Yoshino, Gen
author_facet Sue, Mariko
Yoshihara, Aya
Kuboki, Koji
Hiroi, Naoki
Yoshino, Gen
author_sort Sue, Mariko
collection PubMed
description A 55-year-old Japanese man with a 3-year history of type 2 diabetes mellitus was admitted to our hospital for upper abdominal pain. Control of diabetes mellitus was good with voglibose and metformin, with sitagliptin added to this regimen 8 months prior. His pancreatic enzyme levels were elevated, and abdominal computed tomography (CT) showed diffuse pancreatic swelling with fluid accumulation and ascites of CT grade 3. The patient was diagnosed with severe acute pancreatitis. There were no obvious causes for pancreatitis except the recently administered sitagliptin. Since incretin-related drugs entered the market, the number of incretin-related drugs prescriptions rapidly increased and so did the incidence of pancreatitis. There are several reports suggesting the correlation between incretin-related drugs and pancreatitis, such as a report based on data obtained from the United States Food and Drug Administration (FDA) which revealed a significant correlation between the administration of exenatide or sitagliptin and pancreatitis. However, there also is a report that denied the evidence for such in a large cohort study. The relation between incretin based drugs and pancreatitis is still controversial.
format Online
Article
Text
id pubmed-3576864
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-35768642013-03-05 A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin Sue, Mariko Yoshihara, Aya Kuboki, Koji Hiroi, Naoki Yoshino, Gen Clin Med Insights Case Rep Case Report A 55-year-old Japanese man with a 3-year history of type 2 diabetes mellitus was admitted to our hospital for upper abdominal pain. Control of diabetes mellitus was good with voglibose and metformin, with sitagliptin added to this regimen 8 months prior. His pancreatic enzyme levels were elevated, and abdominal computed tomography (CT) showed diffuse pancreatic swelling with fluid accumulation and ascites of CT grade 3. The patient was diagnosed with severe acute pancreatitis. There were no obvious causes for pancreatitis except the recently administered sitagliptin. Since incretin-related drugs entered the market, the number of incretin-related drugs prescriptions rapidly increased and so did the incidence of pancreatitis. There are several reports suggesting the correlation between incretin-related drugs and pancreatitis, such as a report based on data obtained from the United States Food and Drug Administration (FDA) which revealed a significant correlation between the administration of exenatide or sitagliptin and pancreatitis. However, there also is a report that denied the evidence for such in a large cohort study. The relation between incretin based drugs and pancreatitis is still controversial. Libertas Academica 2013-02-13 /pmc/articles/PMC3576864/ /pubmed/23467428 http://dx.doi.org/10.4137/CCRep.S10856 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Case Report
Sue, Mariko
Yoshihara, Aya
Kuboki, Koji
Hiroi, Naoki
Yoshino, Gen
A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
title A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
title_full A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
title_fullStr A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
title_full_unstemmed A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
title_short A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
title_sort case of severe acute necrotizing pancreatitis after administration of sitagliptin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576864/
https://www.ncbi.nlm.nih.gov/pubmed/23467428
http://dx.doi.org/10.4137/CCRep.S10856
work_keys_str_mv AT suemariko acaseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT yoshiharaaya acaseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT kubokikoji acaseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT hiroinaoki acaseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT yoshinogen acaseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT suemariko caseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT yoshiharaaya caseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT kubokikoji caseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT hiroinaoki caseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin
AT yoshinogen caseofsevereacutenecrotizingpancreatitisafteradministrationofsitagliptin